| [1] |
Ding D, Lawson KD, Kolbe-Alexander TL, et al. The economic burden of physical inactivity: A global analysis of major non-communicable diseases[J]. Lancet, 2016, 388(10051):1311-1324.
doi: 10.1016/S0140-6736(16)30383-X
pmid: 27475266
|
| [2] |
Leucht S, Siafis S, Engel RR, et al. How efficacious are antipsychotic drugs for schizophrenia? an interpretation based on 13 effect size indices[J]. Schizophr Bull, 2022, 48(1):27-36.
doi: 10.1093/schbul/sbab094
URL
|
| [3] |
Semahegn A, Torpey K, Manu A, et al. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis[J]. Syst Rev, 2020, 9(1):17.
doi: 10.1186/s13643-020-1274-3
pmid: 31948489
|
| [4] |
Deng M, Zhai S, Ouyang X, et al. Factors influencing medication adherence among patients with severe mental disorders from the perspective of mental health professionals[J]. BMC Psychiatry, 2022, 22(1):22.
doi: 10.1186/s12888-021-03681-6
pmid: 34996394
|
| [5] |
Clifford L, Crabb S, Turnbull D, et al. A qualitative study of medication adherence amongst people with schizophrenia[J]. Arch Psychiatr Nurs, 2020, 34(4):194-199.
doi: 10.1016/j.apnu.2020.06.002
URL
|
| [6] |
Loots E, Goossens E, Vanwesemael T, et al. Interventions to improve medication adherence in patients with schizophrenia or bipolar disorders: A systematic review and meta-analysis[J]. Int J Environ Res Public Health, 2021, 18(19):10213.
doi: 10.3390/ijerph181910213
URL
|
| [7] |
Xu DR, Gong W, Gloyd S, et al. Measuring adherence to antipsychotic medications for schizophrenia: Concordance and validity among a community sample in rural China[J]. Schizophr Res, 2018, 201:307-314.
doi: S0920-9964(18)30271-8
pmid: 29807806
|
| [8] |
Sajatovic M, Velligan DI, Weiden PJ, et al. Measurement of psychiatric treatment adherence[J]. J Psychosom Res, 2010, 69(6):591-599.
doi: 10.1016/j.jpsychores.2009.05.007
pmid: 21109048
|
| [9] |
Xu DR, Xiao S, He H, et al. Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): A randomized controlled trial[J]. PLoS Med, 2019, 16(4):e1002785.
doi: 10.1371/journal.pmed.1002785
URL
|
| [10] |
McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects[J]. J Clin Epidemiol, 2014, 67(3):267-277.
doi: 10.1016/j.jclinepi.2013.08.015
pmid: 24275499
|
| [11] |
Mehas N, Hudmon KS, Jaynes H, et al. Impact of electronic medication reminder caps on patient adherence and blood pressure[J]. J Pharm Technol, 2021, 37(5):234-243.
|
| [12] |
Yaegashi H, Kirino S, Remington G, et al. Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: A systematic review and meta-analysis[J]. CNS Drugs, 2020, 34(6):579-598.
doi: 10.1007/s40263-020-00713-9
pmid: 32219681
|
| [13] |
Baumgartner PC, Vrijens B, Allemann S, et al. Delta T, a useful indicator for pharmacy dispensing data to monitor medication adherence[J]. Pharmaceutics, 2022, 14(1):103.
doi: 10.3390/pharmaceutics14010103
URL
|
| [14] |
Yalcin-Siedentopf N, Wartelsteiner F, Kaufmann A, et al. Measuring adherence to medication in schizophrenia: The relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics[J]. Int J Neuropsychopharmacol, 2014, 18(5):pyu091.
doi: 10.1093/ijnp/pyu091
URL
|
| [15] |
Smith RL, Tveito M, Kyllesø L, et al. Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs-A study based on blood sample analyses from 24, 239 patients[J]. Eur Neuropsychopharmacol, 2020, 37:64-69.
doi: 10.1016/j.euroneuro.2020.06.007
URL
|
| [16] |
Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017[J]. Pharmacopsychiatry, 2018, 51(1-02):e1.
doi: 10.1055/s-0037-1600991
pmid: 29390205
|
| [17] |
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence[J]. Med Care, 1986, 24(1):67-74.
pmid: 3945130
|
| [18] |
Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new medication adherence rating scale (MARS) for the psychoses[J]. Schizophr Res, 2000, 42(3):241-247.
pmid: 10785582
|
| [19] |
Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity[J]. Psychol Med, 1983, 13(1):17.
doi: 10.1017/S0033291700050029
URL
|
| [20] |
Byerly MJ, Nakonezny PA, Rush AJ. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder[J]. Schizophr Res, 2008, 100(1-3):60-69.
doi: 10.1016/j.schres.2007.12.470
pmid: 18255269
|
| [21] |
Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia[J]. Schizophr Bull, 1994, 20(2):297-310.
pmid: 7916162
|
| [22] |
Brain C, Sameby B, Allerby K, Twelve months of electronic monitoring (MEMS®) in the Swedish COAST-study: A comparison of methods for the measurement of adherence in schizophreni[J]. Eur Neuropsychopharmacol, 2014, 24(2):215-222.
doi: 10.1016/j.euroneuro.2013.11.013
URL
|
| [23] |
Lam WY, Fresco P. Medication adherence measures: An overview[J]. Biomed Res Int, 2015, 2015:217047.
|
| [24] |
Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications[J]. Psychiatr Serv, 2007, 58(9):1187-1192.
doi: 10.1176/ps.2007.58.9.1187
URL
|
| [25] |
Kwan YH, Weng SD, Loh DHF, et al. Measurement properties of existing patient-reported outcome measures on medication adherence: Systematic review[J]. J Med Internet Res, 2020, 22(10):e19179.
doi: 10.2196/19179
URL
|
)
